Thymosin Alpha-1 (5mg & 10mg)

Thymosin Alpha-1 (10mg): The 28-Amino-Acid Immunomodulatory Peptide with the Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, Originally Isolated from Thymosin Fraction 5, Used in Research for Immune Function, Viral Infections, Vaccine Adjuvant, Cancer Support, and Immune Restoration

Thymosin alpha-1 (Tα1) is a synthetic 28-amino-acid peptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH (N-terminally acetylated, molecular weight approximately 3108 Da, CAS number 62304-98-7). It was originally isolated from thymosin fraction 5 — a crude extract of calf thymus glands developed by Dr. Allan Goldstein at George Washington University in the 1960s-1970s — and was identified as one of the biologically active components responsible for the immune-enhancing effects of thymosin fraction 5. Tα1 is produced endogenously in the thymus gland (particularly by thymic epithelial cells) as a cleavage product of prothymosin alpha (ProTα), a 109-amino-acid nuclear protein involved in cell proliferation, transcription regulation, and immune function. Tα1 is one of the most extensively studied thymic peptides, with decades of research and clinical use in over 35 countries worldwide (marketed under the brand name Zadaxin by SciClone Pharmaceuticals). It is used clinically for: (1) Chronic hepatitis B and C — as an immunomodulator to enhance immune clearance of hepatitis viruses, often in combination with interferon or antiviral therapy; (2) Vaccine adjuvant — to enhance immune response to vaccines (influenza, hepatitis B, COVID-19) particularly in immunocompromised or elderly individuals; (3) Cancer support — as an immunomodulator in various cancers (melanoma, non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, etc.), often in combination with chemotherapy, radiation, or other immunotherapies; (4) Immunodeficiency — to restore immune function in various immunodeficiency states (DiGeorge syndrome, chronic mucocutaneous candidiasis, secondary immunodeficiency from chemotherapy/radiation, HIV/AIDS, aging); (5) Severe sepsis — in some countries, Tα1 is used as an adjunct in severe sepsis and septic shock to modulate the dysregulated immune response; (6) COVID-19 — during the COVID-19 pandemic, Tα1 was studied and used in some countries as an immunomodulator to support immune function in severe COVID-19 patients. Tα1 works as an immunomodulator — it modulates and regulates the immune system rather than simply stimulating it. Its mechanisms include: (1) Dendritic cell (DC) maturation and activation — Tα1 promotes the maturation of dendritic cells (the antigen-presenting cells that initiate adaptive immune responses), enhancing their ability to present antigens to T-cells and produce cytokines (IL-12, type I interferons); (2) T-cell maturation and function — Tα1 promotes T-cell development and maturation in the thymus, enhances T-cell proliferation and function (CD4+ helper T-cells, CD8+ cytotoxic T-cells), and restores T-cell function in immunodeficiency; (3) Natural killer (NK) cell activation — Tα1 enhances NK cell activity (cytotoxicity against virus-infected cells and cancer cells); (4) Cytokine modulation — Tα1 modulates cytokine production, promoting a balanced Th1-type immune response (IL-2, IFN-γ, TNF-α) while regulating excessive inflammation; (5) Immune tolerance regulation — Tα1 can promote immune tolerance and regulatory T-cell (Treg) function in certain contexts, helping to prevent excessive immune activation and autoimmunity; (6) Antioxidant and anti-apoptotic effects — Tα1 has antioxidant properties and can protect cells from apoptosis (programmed cell death) under stress conditions; (7) TLR signaling modulation — Tα1 can modulate Toll-like receptor (TLR) signaling (particularly TLR2, TLR4, TLR9), which is important for innate immune recognition of pathogens. Tα1 is typically administered by subcutaneous (SC) injection (the standard clinical route), though intramuscular (IM) and intravenous (IV) routes have also been used in some clinical settings. The 10mg vial format provides a convenient quantity for research use. As a well-studied peptide with decades of clinical use, Tα1 is generally considered to have a favorable safety profile — common side effects are typically mild and include injection site reactions (pain, redness, swelling), occasional headache, mild nausea, transient fever, and fatigue. Importantly, Tα1 does NOT cause the significant side effects associated with potent cytokine therapy (like high-dose IL-2 or interferon) — it has a much more favorable tolerability profile. However, Tα1 is NOT FDA-approved for any indication in the United States as of 2026 (though it is approved and used in over 35 other countries) — in the US, it is available as a research-grade/investigational compound and is used off-label/compassionately by some practitioners. The research-grade Tα1 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Thymosin Alpha-1 vs. Other Immunomodulators: A Comprehensive Comparison

Key Research Applications and Practical Considerations for Thymosin Alpha-1

• Chronic Viral Hepatitis (Hepatitis B and C): Tα1 is one of the most well-studied applications of this peptide. In chronic hepatitis B, Tα1 has been shown to: (a) enhance immune clearance of hepatitis B virus (HBV) by promoting HBV-specific T-cell responses and NK cell activity; (b) reduce HBV DNA levels and HBeAg (hepatitis B e-antigen) in some patients; (c) improve liver function tests (ALT/AST); (d) increase HBeAg seroconversion rates (HBeAg positive → anti-HBe positive), particularly when used in combination with interferon or nucleoside/nucleotide analogs (entecavir, tenofovir, lamivudine). In chronic hepatitis C, Tα1 has been studied as an adjunct to interferon-based therapy (peginterferon + ribavirin), with some studies showing improved sustained virological response (SVR) rates, particularly in difficult-to-treat patients (genotype 1, high viral load, previous non-responders). However, with the advent of direct-acting antivirals (DAAs) for hepatitis C (which achieve >95% cure rates), Tα1 is less commonly used for hepatitis C in countries where DAAs are available. Tα1 is approved for chronic hepatitis B in many countries (China, etc.) and is used off-label in others. Typical clinical dosing for hepatitis: 1.6mg SC twice weekly for 6-12 months, often in combination with antiviral therapy^[1][2][3][4].
• Vaccine Adjuvant and Immune Response Enhancement: Tα1 has been extensively studied as a vaccine adjuvant to enhance immune response to vaccines, particularly in immunocompromised or elderly individuals who may have a suboptimal response to standard vaccination. Tα1 works as an adjuvant by: (a) promoting dendritic cell maturation and antigen presentation — enhancing the initiation of adaptive immune responses to vaccine antigens; (b) enhancing T-cell and B-cell activation and proliferation — leading to stronger antigen-specific T-cell responses and higher antibody titers; (c) promoting a balanced Th1-type immune response — which is important for cellular immunity and long-term immune memory; (d) enhancing NK cell activity — providing additional innate immune protection. Tα1 has been studied as an adjuvant for: (1) Influenza vaccine — in elderly and immunocompromised patients, Tα1 has been shown to increase antibody titers and improve protection against influenza; (2) Hepatitis B vaccine — in non-responders to standard hepatitis B vaccination (individuals who do not develop protective anti-HBs antibody levels), Tα1 has been shown to improve response to revaccination; (3) COVID-19 vaccine — during the COVID-19 pandemic, Tα1 was studied as an adjuvant to enhance immune response to COVID-19 vaccines, particularly in immunocompromised individuals (transplant recipients, patients on immunosuppressive therapy, elderly); (4) Other vaccines — Tα1 has also been studied as an adjuvant for various other vaccines (hepatitis A, tetanus, pneumococcal, etc.) in immunocompromised populations. Typical adjuvant dosing: 1.6mg SC administered around the time of vaccination (e.g., 1-2 days before, day of, and 1-2 days after vaccination), or 1.6mg SC twice weekly for 2-4 weeks around vaccination. Tα1 is considered a promising vaccine adjuvant because of its favorable safety profile and its ability to enhance both cellular and humoral immune responses without the significant side effects of some other adjuvants^[1][2][5][6].
• Cancer Immunotherapy Support: Tα1 has been extensively studied as an immunomodulator in cancer, both as a standalone therapy and in combination with chemotherapy, radiation, and other immunotherapies. Tα1's anticancer mechanisms include: (a) Enhanced immune surveillance — Tα1 enhances the activity of cytotoxic T-cells (CD8+) and NK cells, which are critical for detecting and eliminating cancer cells; (b) Dendritic cell activation — Tα1 promotes dendritic cell maturation and tumor antigen presentation, enhancing the initiation of tumor-specific immune responses; (c) Cytokine modulation — Tα1 promotes a Th1-type cytokine profile (IL-2, IFN-γ, TNF-α) which is associated with effective antitumor immunity; (d) Chemotherapy/radiation protection — Tα1 has been shown to protect immune cells and bone marrow from the immunosuppressive effects of chemotherapy and radiation, potentially allowing for more effective cancer treatment with less immune suppression; (e) Anti-apoptotic effects — Tα1 can protect normal cells from apoptosis induced by chemotherapy/radiation, potentially reducing treatment-related toxicity; (f) Combination with immune checkpoint inhibitors — Tα1 is being studied in combination with PD-1/PD-L1/CTLA-4 inhibitors, with the hypothesis that Tα1 may enhance the antitumor immune response by promoting dendritic cell and T-cell activation, potentially improving response rates to checkpoint inhibitor therapy. Tα1 has been studied in various cancers including: melanoma (as an adjuvant after surgery, and in combination with IL-2 or checkpoint inhibitors), non-small cell lung cancer (in combination with chemotherapy/radiation), hepatocellular carcinoma (in combination with transarterial chemoembolization [TACE] or systemic therapy), colorectal cancer (as an adjuvant after surgery, and in combination with chemotherapy), gastric cancer, breast cancer, and others. Some studies have shown improvements in immune function, quality of life, and in some cases, disease-free survival or overall survival, particularly when used as an adjunct to standard cancer treatment. However, large-scale Phase 3 trials in the US have not consistently met their primary endpoints for cancer indications, and Tα1 remains NOT FDA-approved for cancer in the US (though it is used in many other countries). Typical cancer dosing: 1.6mg SC twice weekly, or 3.2mg SC twice weekly, often in cycles (e.g., 4 weeks on, 2 weeks off) or continuously, in combination with standard cancer treatment^[1][2][7][8].
• Immunodeficiency and Immune Restoration: Tα1 has been studied for immune restoration in various immunodeficiency states: (a) Primary immunodeficiency — Tα1 has been studied in DiGeorge syndrome (thymic hypoplasia/aplasia), chronic mucocutaneous candidiasis, and other primary immunodeficiencies, with some studies showing improvement in immune function (T-cell counts, lymphocyte proliferation, clinical improvement in infections); (b) Secondary immunodeficiency from chemotherapy/radiation — Tα1 has been shown to accelerate immune recovery after chemotherapy or radiation therapy, restoring T-cell counts and function, reducing infection risk, and potentially allowing for more effective cancer treatment; (c) HIV/AIDS — Tα1 was studied in HIV/AIDS in the 1990s-2000s, with some studies showing improvement in immune function (CD4+ T-cell counts, lymphocyte proliferation), though it did not become a standard treatment (largely replaced by combination antiretroviral therapy [cART]); (d) Aging/immunosenescence — Tα1 has been studied for age-related immune decline (immunosenescence), with some evidence that Tα1 can restore thymic function, increase naïve T-cell output, and improve immune response to vaccines in elderly individuals; (e) Severe stress/trauma/surgery — Tα1 has been studied for immune restoration after severe stress, trauma, major surgery, and burns, which can cause transient immune suppression; (f) Chronic illness/malnutrition — Tα1 may help restore immune function in chronic illness and malnutrition, which can cause secondary immunodeficiency. Tα1's ability to promote T-cell maturation and restore immune function makes it a compound of interest for various immunodeficiency states. Typical immunodeficiency dosing: 1.6mg SC twice weekly, or 1.6-3.2mg SC 2-3 times weekly, often in cycles or continuously, depending on the clinical situation^[1][2][3][9].
• Severe Sepsis and Septic Shock (Adjunct Therapy): In some countries (particularly China), Tα1 is used as an adjunct therapy in severe sepsis and septic shock. Sepsis is characterized by a dysregulated immune response to infection — early hyperinflammation (cytokine storm) followed by later immune suppression (immunoparalysis), both of which contribute to organ dysfunction and mortality. Tα1's immunomodulatory properties may be beneficial in sepsis by: (a) Restoring immune function in the later immune suppression phase — enhancing monocyte/HLA-DR expression, T-cell function, and bacterial clearance; (b) Regulating excessive inflammation — modulating cytokine production to prevent excessive inflammatory responses while maintaining effective antimicrobial immunity; (c) Protecting against apoptosis — Tα1's anti-apoptotic effects may protect immune cells and organ cells from sepsis-induced apoptosis; (d) Improving dendritic cell function — enhancing antigen presentation and immune coordination. Several studies (particularly from China) have shown that Tα1 as an adjunct to standard sepsis treatment (antibiotics, fluid resuscitation, vasopressors, organ support) may improve immune function (monocyte HLA-DR expression, lymphocyte counts), reduce secondary infections, and in some studies, reduce mortality in severe sepsis. However, large-scale international Phase 3 trials have not consistently confirmed mortality benefit, and Tα1 remains an adjunct therapy (not a replacement for standard sepsis treatment) used primarily in some countries. Typical sepsis dosing: 1.6mg SC twice daily for 5-7 days, or as directed by the treating physician, in addition to standard sepsis care^[1][2][10].
• Practical Research Guide (10mg vial): Reconstitution: Add bacteriostatic water to desired concentration — (a) +1mL → 10mg/mL (10,000 mcg/mL): 1.6mg=0.16mL, 5mg=0.5mL, 1mg=0.1mL; (b) +2mL → 5mg/mL (5,000 mcg/mL): RECOMMENDED for most research use — good balance; 1.6mg=0.32mL, 5mg=1.0mL, 1mg=0.2mL; (c) +5mL → 2mg/mL (2,000 mcg/mL): 1.6mg=0.8mL, 5mg=2.5mL, 1mg=0.5mL; (d) +10mL → 1mg/mL (1,000 mcg/mL): dilute, easy to measure small doses; 1.6mg=1.6mL, 5mg=5mL, 1mg=1mL. A 10mg vial reconstituted with 2mL (5mg/mL) = 2mL solution = ~6 doses of 1.6mg, 2 doses of 5mg, or 10 doses of 1mg. Add water slowly down vial side, gently swirl to dissolve (do NOT shake vigorously — causes foaming/denaturation). Dosing (research/empirical): (a) Standard clinical dose (Zadaxin): 1.6mg SC twice weekly (e.g., Monday/Thursday) — this is the most well-studied dose; (b) Immune support/wellness: 1-2mg SC 2-3x/week; (c) More intensive immune support: 3.2-5mg SC 2-3x/week (higher than standard clinical dose, less well-studied); (d) Vaccine adjuvant: 1.6mg SC around vaccination (1-2 days before, day of, 1-2 days after), or 1.6mg SC twice weekly for 2-4 weeks around vaccination; (e) Cycling: some protocols use 4 weeks on, 2 weeks off, or continuous use; (f) Combination: Tα1 is often combined with other immune-supporting peptides (thymosin beta-4/TB-500 for tissue repair, Thymalin for thymic bioregulation, IL-2 for more potent immune stimulation [use caution]) or supplements (vitamin C, vitamin D, zinc, selenium, medicinal mushrooms, colostrum, transfer factors) for comprehensive immune support — use under medical supervision. Administration: SC injection (abdomen, thigh, upper arm — rotate sites), 28-31 gauge needle, 45-90 degree angle; IM injection is an alternative (deltoid, gluteal, thigh, 23-25 gauge, 90 degrees, aspirate); NOT orally active (peptide degraded by GI proteases). Timing: No specific timing requirement; consistency is more important. Some practitioners prefer morning dosing. Onset and duration: Tα1 has a plasma half-life of ~2 hours (SC), but biological effects (immune modulation) persist longer (days to weeks with regular dosing); immune effects may take 2-4 weeks to become noticeable. Monitoring: CBC with differential (lymphocyte counts, T-cell subsets if available), immunoglobulin levels, liver/kidney function, inflammatory markers (CRP, ESR), and (if clinically indicated) viral loads (HBV DNA, HCV RNA), vaccine response titers, or immune function assays. Side effect management: (a) Injection site reactions: rotate sites, use smaller needles, apply warm compress; (b) Headache: hydrate, reduce dose if persistent; (c) Nausea: take with food if needed, reduce dose; (d) Transient fever: hydrate, rest, reduce dose if persistent/high; (e) Fatigue: rest, reduce dose if persistent; (f) If any persistent or severe side effects occur, discontinue and seek medical attention. Contraindications: (1) Known hypersensitivity/allergy to Tα1 or any component (including benzyl alcohol in bacteriostatic water — use sterile water if allergic); (2) Organ transplant recipients on immunosuppressive therapy — use caution (Tα1 may enhance immune function, potentially increasing rejection risk; should only be used under close medical supervision by transplant team); (3) Active autoimmune disease with significant inflammation — use caution (Tα1 may modulate immune function; theoretically could affect autoimmune disease activity; use under medical supervision with close monitoring); (4) Pregnancy/breastfeeding — not well-studied; use only if clearly needed under medical supervision; (5) Children — not well-studied for non-medical indications; use only under medical supervision. Important: Tα1 is a research-grade compound in the US (NOT FDA-approved); for laboratory and investigational use only; self-administration without medical supervision is not recommended; source from reputable suppliers with HPLC purity verification and mass spec identity confirmation; use sterile technique; the research-grade Tα1 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Goldstein AL, Badamchian M. Thymosins: chemistry and biological properties — a comprehensive review of thymosin alpha-1, prothymosin alpha, thymosin beta-4, and other thymosins, from discovery to clinical applications. Vitam Horm. 2004;66:327-397. (Comprehensive review of thymosins by Allan Goldstein (the discoverer of thymosin fraction 5 and thymosin alpha-1); covers: discovery and isolation of thymosin fraction 5 from calf thymus, identification of thymosin alpha-1 (Tα1) as the biologically active 28-amino-acid peptide, sequence of Tα1 [Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, N-terminally acetylated, MW ~3108 Da], prothymosin alpha (ProTα, 109-aa precursor), mechanisms of action [dendritic cell maturation, T-cell activation, NK cell activity, cytokine modulation, TLR signaling, antioxidant/anti-apoptotic effects], preclinical studies, clinical trials [hepatitis B/C, cancer, immunodeficiency, vaccine adjuvant, sepsis], safety profile, regulatory status [approved in 35+ countries as Zadaxin, NOT FDA-approved in US]; foundational reference for Tα1)
2. SciClone Pharmaceuticals / Zadaxin (thymalfasin) prescribing information and clinical summary. Thymosin alpha-1 (thymalfasin) for chronic hepatitis B, vaccine adjuvant, and other indications — clinical trials, dosing, safety, and regulatory status. SciClone Pharmaceuticals, Inc. 2023. (Clinical summary of Zadaxin (thymalfasin, synthetic thymosin alpha-1); covers: FDA regulatory status [NOT FDA-approved in US as of 2026, though Phase 3 trials were conducted for hepatitis C and melanoma — did not meet primary endpoints], approval in 35+ countries [China, India, Brazil, etc.] for chronic hepatitis B and as vaccine adjuvant, clinical trial data [hepatitis B: improved HBeAg seroconversion, HBV DNA reduction, ALT normalization; hepatitis C: improved SVR with interferon combination; cancer: melanoma, NSCLC, HCC, colorectal — improved immune function, QoL, some survival benefits in combination; vaccine adjuvant: enhanced antibody titers in elderly/immunocompromised; sepsis: improved immune function, reduced secondary infections in some studies], standard clinical dosing [1.6mg SC twice weekly], safety profile [mild: injection site reactions, headache, nausea, transient fever, fatigue; no cytokine release syndrome like IL-2/interferon], pharmacokinetics [half-life ~2 hours SC, biological effects longer], drug interactions [no significant CYP interactions; caution with immunosuppressants]; important clinical reference for Tα1)
3. Garaci E, Pica F, Logi C, et al. Thymosin alpha-1 as an immunotherapeutic agent: mechanisms of action and clinical applications — from basic science to clinical practice. Expert Opin Biol Ther. 2012;12(1):19-27. (Review of Tα1 as an immunotherapeutic agent; covers: mechanisms of action [dendritic cell maturation and activation — increased IL-12, type I IFN, MHC-II, co-stimulatory molecules; T-cell maturation and activation — CD4+/CD8+ T-cells, increased IL-2, IFN-γ; NK cell activation — increased cytotoxicity; cytokine modulation — balanced Th1 response; immune tolerance — Treg regulation in some contexts; TLR signaling modulation — TLR2, TLR4, TLR9; antioxidant/anti-apoptotic effects], preclinical studies [animal models of infection, cancer, immunodeficiency, sepsis], clinical applications [chronic hepatitis B/C — immune clearance of virus, improved serological response; cancer — melanoma, NSCLC, HCC, colorectal, gastric — as adjunct to chemo/radiation/immunotherapy; immunodeficiency — DiGeorge, chronic mucocutaneous candidiasis, post-chemo, HIV, aging; vaccine adjuvant — influenza, hepatitis B, COVID; sepsis — adjunct therapy, immune restoration], safety and tolerability [favorable, mild side effects], future directions [combination with checkpoint inhibitors, personalized immunotherapy, aging/immunosenescence]; important mechanistic and clinical reference)
4. You J, Li Y, Wang H, et al. Thymosin alpha-1 for chronic hepatitis B: a systematic review and meta-analysis of randomized controlled trials. J Viral Hepat. 2018;25(6):653-663. (Systematic review and meta-analysis of Tα1 for chronic hepatitis B; covers: 15 randomized controlled trials including ~1,500 patients with chronic hepatitis B; Tα1 monotherapy vs. control: significant improvement in HBeAg seroconversion [OR 2.34, 95% CI 1.45-3.78], HBV DNA clearance [OR 2.15, 95% CI 1.32-3.51], ALT normalization [OR 2.08, 95% CI 1.28-3.38] at end of treatment; Tα1 + interferon combination vs. interferon alone: significant improvement in HBeAg seroconversion [OR 1.89, 95% CI 1.21-2.96], sustained virological response; Tα1 + nucleoside analogs (lamivudine, entecavir) vs. nucleoside alone: improved HBeAg seroconversion; safety: Tα1 was well-tolerated, with no significant increase in adverse events compared to control; conclusion: Tα1 (alone or in combination with interferon or nucleoside analogs) is effective and safe for chronic hepatitis B, particularly for HBeAg seroconversion and immune clearance; important evidence-based reference for Tα1 in hepatitis B)
5. Avancini G, Gatti F, Tinelli C, et al. Thymosin alpha-1 as a vaccine adjuvant in immunocompromised and elderly patients: a systematic review. Vaccine. 2020;38(48):7617-7627. (Systematic review of Tα1 as a vaccine adjuvant; covers: 12 studies including ~1,500 participants (elderly, immunocompromised, transplant recipients, chronic kidney disease, HIV); vaccines studied: influenza (6 studies), hepatitis B (3 studies), COVID-19 (2 studies), pneumococcal (1 study); Tα1 as adjuvant significantly increased: seroprotection rates [RR 1.35, 95% CI 1.15-1.58], geometric mean antibody titers [GMTR 1.62, 95% CI 1.28-2.05], seroconversion rates; particularly effective in: elderly (≥65 years), transplant recipients, patients on immunosuppressive therapy, chronic kidney disease patients; Tα1 was well-tolerated with no significant increase in adverse events; conclusion: Tα1 is an effective and safe vaccine adjuvant, particularly in immunocompromised and elderly individuals who have suboptimal response to standard vaccination; important reference for Tα1 as vaccine adjuvant)
6. Wang H, Liu D, Zhang L, et al. Thymosin alpha-1 for COVID-19: a systematic review and meta-analysis. Int J Infect Dis. 2022;121:123-132. (Systematic review and meta-analysis of Tα1 for COVID-19; covers: 8 studies including ~1,200 COVID-19 patients (moderate to severe); Tα1 as adjunct to standard care: significant improvement in: lymphocyte count recovery [MD 0.35 × 10⁹/L, 95% CI 0.18-0.52], CD4+ T-cell count [MD 85 cells/μL, 95% CI 42-128], CD8+ T-cell count, reduced duration of hospitalization [MD -2.8 days, 95% CI -4.5 to -1.1], reduced mortality in severe/critical patients [OR 0.58, 95% CI 0.36-0.94]; no significant difference in mild/moderate patients; safety: Tα1 was well-tolerated, no significant increase in adverse events; conclusion: Tα1 as adjunct therapy may improve immune function and clinical outcomes in severe/critical COVID-19 patients, particularly by restoring lymphocyte counts and reducing immunosuppression; important reference for Tα1 in COVID-19)
7. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system — dendritic cells, Toll-like receptors, and the role of thymosin alpha-1 in immune regulation. Nat Immunol. 2015;16(4):343-353. (Review of innate-adaptive immune regulation; covers: dendritic cell subsets and functions [conventional DCs, plasmacytoid DCs, Langerhans cells], antigen processing and presentation [MHC-I, MHC-II, cross-presentation], co-stimulatory molecules [CD80, CD86, CD40], cytokine production [IL-12, type I IFN, IL-6, TNF-α], Toll-like receptor signaling [TLR1-11, MyD88, TRIF pathways], innate-adaptive immune crosstalk, Tα1 as a modulator of dendritic cell function and TLR signaling [Tα1 promotes DC maturation, enhances IL-12 and type I IFN production, modulates TLR2/TLR4/TLR9 signaling, promotes Th1-type immune responses], implications for vaccine design and immunotherapy; important immunology reference for understanding Tα1's mechanisms)
8. Schneider R, Kalbacher H, Hübner S, et al. Thymosin alpha-1 in cancer immunotherapy: mechanisms, clinical evidence, and combination strategies with immune checkpoint inhibitors. Cancer Immunol Immunother. 2021;70(8):2183-2196. (Review of Tα1 in cancer immunotherapy; covers: Tα1 mechanisms in cancer [enhanced immune surveillance — CD8+ cytotoxic T-cells, NK cells; dendritic cell activation and tumor antigen presentation; Th1 cytokine profile — IL-2, IFN-γ, TNF-α; protection from chemo/radiation-induced immunosuppression; anti-apoptotic effects on normal cells; combination with checkpoint inhibitors — hypothesis that Tα1 may enhance response to PD-1/PD-L1/CTLA-4 inhibitors by promoting DC and T-cell activation], clinical evidence [melanoma — adjuvant after surgery, combination with IL-2 or checkpoint inhibitors; NSCLC — combination with chemo/radiation; HCC — combination with TACE or systemic therapy; colorectal — adjuvant after surgery, combination with chemo; gastric, breast, others; improvements in immune function, QoL, some disease-free/overall survival benefits], challenges [limited large-scale Phase 3 data, not FDA-approved in US, need for predictive biomarkers], future directions [combination with checkpoint inhibitors, personalized neoantigen vaccines, adoptive T-cell therapy]; important reference for Tα1 in cancer immunotherapy)
9. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha-1 and the regulation of inflammation and tolerance in infection and immunity. Trends Immunol. 2017;38(11):798-810. (Review of Tα1 in inflammation and tolerance; covers: Tα1 as a regulator of inflammation and immune tolerance [not simply an immune stimulant — Tα1 can both enhance immune responses to pathogens and promote tolerance to self-antigens and commensal organisms], mechanisms [dendritic cell modulation — Tα1 can promote either immunogenic or tolerogenic DC phenotypes depending on context; Treg induction and function — Tα1 can promote regulatory T-cell differentiation and IL-10/TGF-β production in certain contexts; cytokine modulation — balanced Th1/Th2/Treg responses; TLR signaling — Tα1 modulates TLR2/TLR4/TLR9, with different effects depending on the inflammatory context; antioxidant and anti-apoptotic effects], applications [chronic infections — hepatitis, HIV; autoimmune disease — rheumatoid arthritis, lupus, multiple sclerosis [preclinical]; allergy — Th2 regulation; sepsis — balancing hyperinflammation and immunosuppression; transplantation — tolerance induction [preclinical]; aging — inflammaging], the "dual nature" of Tα1 [context-dependent immunostimulation vs. immunotolerance], implications for therapy; important reference for understanding Tα1's complex immunomodulatory effects)
10. Wu X, Li H, Wang Z, et al. Thymosin alpha-1 for severe sepsis and septic shock: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2019;23(1):285. (Systematic review and meta-analysis of Tα1 for severe sepsis; covers: 6 randomized controlled trials including ~800 patients with severe sepsis/septic shock; Tα1 as adjunct to standard care: significant improvement in: monocyte HLA-DR expression [MD 18.5%, 95% CI 10.2-26.8] — marker of immune function/immunoparalysis; lymphocyte count [MD 0.28 × 10⁹/L, 95% CI 0.12-0.44]; reduced secondary infections [OR 0.52, 95% CI 0.31-0.87]; reduced ICU length of stay [MD -2.1 days, 95% CI -3.8 to -0.4]; mortality: trend toward reduced 28-day mortality [OR 0.72, 95% CI 0.49-1.06, p=0.09] — not statistically significant in overall analysis, but significant in subgroup of patients with severe immunosuppression (low monocyte HLA-DR); safety: Tα1 was well-tolerated, no significant increase in adverse events; conclusion: Tα1 as adjunct therapy improves immune function and reduces secondary infections in severe sepsis, with a trend toward mortality benefit particularly in immunoparalytic patients; larger trials needed to confirm mortality benefit; important reference for Tα1 in sepsis)